CD20 Protein, Human, Recombinant (His & Avi), Biotinylated

Catalog No. TMPK-00184 Copy Product Info

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.

CD20 Protein, Human, Recombinant (His & Avi), Biotinylated

Catalog No. TMPK-00184

Copy Product Info

CD20 Protein, Human, Recombinant (His & Avi), Biotinylated

Pack Size	Price	USA Stock	Global Stock
5 μg	$91	7-10 days	7-10 days
10 μg	$148	7-10 days	7-10 days
20 μg	$245	7-10 days	7-10 days
50 μg	$483	7-10 days	7-10 days
100 μg	$813	7-10 days	7-10 days
200 μg	$1,470	7-10 days	7-10 days
500 μg	$3,250	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Biotinylated Human CD20, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 87.3ng/ml determined by ELISA.
Description	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.
Species	Human
Expression System	E. coli
Tag	C-His-Avi
Accession Number	P11836-1
Synonyms	MS4A-1,MS4A1,Membrane-spanning 4-domains subfamily A member 11,Leukocyte surface antigen Leu-16,CD20,Bp35,B-lymphocyte surface antigen B1
Construction	Ile141-Ser188
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	16.8 kDa (predicted) same as Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Supplied as 0.22 μm filtered solution in 20 mM PB , 10% Glycerol (pH 7.0).
Stability & Storage	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	Proteins are shipped with blue ice.
Research Background	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.